Search Results
Apr 15, 2026, 07:00 ET Concentrated Shatavari Nutraceutical Gummy Leads TopGum's New Women's Collection
heart of TopGum's collection is its SRI-81™ shatavari (Asparagus racemocas) gummy with vitamin D. Each naturally flavored cherry chew packs in 150mg clinically endorsed SRI-80 shatavari root extract combined with 5mcg vitamin D. Labelled the "Queen of Herbs" in Ayurveda, shatavari is a purported adaptogen
More news about: TopGum Industries, Inc.
Apr 15, 2026, 07:00 ET Steamed Ginger Extract by 3H LABS Supports Weight Loss
enrolled 80 overweight adults with a high body mass index (BMI). Led by Jeong Eun Kwon, PhD, the researchers assigned participants to either a daily 480mg dose of Zinoact™ or an identical placebo while being instructed to maintain their usual diets and physical activity routines.Following 12 weeks
More news about: 3H LABS
Apr 15, 2026, 07:00 ET UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
The company is presenting 21 abstracts in total from its innovative neurology portfolio (14 epilepsy and 7 rare disease including 6 myasthenia gravis (MG) abstracts) at the American Academy of Neurology (AAN) 2026 Annual Meeting (April 18-22, 2026).
More news about: UCB
Apr 15, 2026, 05:28 ET Chill Spritz Takes Flight with airBaltic -- and Your Next Journey Just Got an Upgrade
Chill Spritz is a functional, alcohol-free sparkling drink infused with ashwagandha (500 mg), traditionally associated with relaxation and wellbeing in herbal practices. With a zero-sugar, zero-calorie, and caffeine-free formulation, the
More news about: Chill Spritz
Apr 14, 2026, 14:12 ET GORGIE DROPS NEW CANDY TWIST FLAVOR, BRINGING A PLAYFUL TAKE ON BETTER-FOR-YOU ENERGY
the new flavor is designed for modern routines, from morning pick-me-ups to afternoon slumps and everything in between. Each can of GORGIE features 150mg of green tea caffeine, plus functional wellness and beauty benefits, including Biotin, B Vitamins, and L-Theanine for a smooth, energizing boost without
More news about: GORGIE
Apr 14, 2026, 09:30 ET Woodstock Libations Launches Statewide in Connecticut
(Laugh) — 2.5mg THC, 2.5mg CBC, 2.5mg CBG + Lion's Mane, ReishiYuzu Ginger (Chill) — 2.5mg THC + 10mg CBD, 2.5mg CBC + Cordyceps, L-TheanineDark Berries (Dream) — 2.5mg THC + 10mg CBD, 2.5mg CBN + Reishi, L-TheanineEach
More news about: Woodstock Goods
Apr 14, 2026, 09:00 ET MISTRAS Group Receives Frost & Sullivan's 2026 Global NDT Field Inspection Services Company of the Year Recognition for Excellence in Integrated Asset Integrity and Digital Execution
[email protected] MISTRAS Group, Inc.MISTRAS Group, Inc. (NYSE: MG) is a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, serving critical strategic markets including oil
More news about: Frost & Sullivan
Apr 14, 2026, 09:00 ET MISTRAS Group Receives Frost & Sullivan's 2026 Global NDT Field Inspection Services Company of the Year Recognition for Excellence in Integrated Asset Integrity and Digital Execution
[email protected] MISTRAS Group, Inc.MISTRAS Group, Inc. (NYSE: MG) is a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, serving critical strategic markets including oil
More news about: Frost & Sullivan
Apr 14, 2026, 08:56 ET PLT Health Solutions to Showcase New Ingredients and New Clinical Studies at Vitafoods Europe
cartilage preservation. In 2025, PLT announced a new study on its Dynagenix® Muscle+Joint Formula ingredient that demonstrated that just 40 mg/day of Dynagenix led to statistically significant improvements in joint comfort, stiffness, and function as early as 5 days after initial supplementation.
More news about: PLT Health Solutions
Apr 14, 2026, 08:30 ET Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic
More news about: Neurocrine Biosciences, Inc.
Apr 14, 2026, 08:05 ET Lucky Energy Takes Energy Gummies into Retail Following Strong DTC Debut
a compact, portable format suited for moments when drinks are less practical, from gym bags and festivals to travel.Each serving delivers 128 mg of caffeine, along with a simple, functional blend of maca, ginseng, beta-alanine, L-theanine, and taurine, formulated to support more balanced, sustained
More news about: Lucky Beverage Company
Apr 13, 2026, 20:00 ET 双双入選2026 SGO口頭報告：蘆康沙妥珠單抗(sac-TMT)兩項婦科腫瘤研究成果發佈
為鉑敏感複發性卵巢癌的維持療法，展現出積極的療效信號與良好的安全性，為該聯合方案在卵巢癌人群中的進一步臨床探索提供了重要依據。宮頸癌宮頸癌佇列共納入68例既往經治的二線或三線復發或轉移性宮頸癌患者，分別接受蘆康沙妥珠單抗(sac-TMT) 3mg/kg、4mg/kg及5mg/kg Q2W聯合帕博利珠單抗治療。入組患者中57%既往接受過貝伐珠單抗治療，51%既往接受過免疫治療。中位隨訪時間為24.7個月(數據截止日期為2025年11月17日)。數據顯示，患者接受蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗治療後，總人群的客觀緩解率
More news about: 科倫博泰
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
second-line or third-line recurrent or metastatic cervical cancer were enrolled in the cervical cancer cohort to receive sac-TMT at doses of 3 mg/kg, 4 mg/kg, or 5 mg/kg Q2W in combination with pembrolizumab. Among the enrolled patients, 57% had prior bevacizumab therapy, and 51% had prior immunotherapy.
More news about: Kelun-Biotech
Apr 13, 2026, 11:00 ET DKT LATAM Norte refuerza la conversación sobre anticonceptivos de emergencia en México con Alina
emergencia distribuida por DKT LATAM Norte, se integra a la conversación sobre acceso, información y derechos reproductivos. Con una formulación de 1.5 mg de levonorgestrel, Alina puede alcanzar más del 97% de eficacia si se administra dentro de las primeras 24 horas posteriores a una relación sexual
More news about: DKT
Apr 13, 2026, 07:00 ET UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
(ZLP-PFS)1UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis (MG) abstracts at AAN 2026ATLANTA, April 13, 2026 /PRNewswire/ --
More news about: UCB
Apr 13, 2026, 06:45 ET Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.INDICATIONS FOR JAYPIRCA (pirtobrutinib)Jaypirca
More news about: Eli Lilly and Company
Apr 13, 2026, 03:43 ET Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
calcitonin gene-related peptide (CGRP) which was purposefully developed for intravenous (IV) administration. The efficacy and safety of eptinezumab 100 mg and 300 mg was investigated in two Phase 3 clinical trials (PROMISE-1 in episodic migraine[vi] and PROMISE-2 in chronic migraine)[vii],
More news about: H. Lundbeck A/S
Apr 13, 2026, 03:40 ET Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
calcitonin gene-related peptide (CGRP) which was purposefully developed for intravenous (IV) administration. The efficacy and safety of eptinezumab 100 mg and 300 mg was investigated in two Phase 3 clinical trials (PROMISE-1 in episodic migraine[vi] and PROMISE-2 in chronic migraine)[vii],
More news about: H. Lundbeck A/S
Apr 10, 2026, 13:03 ET Lupin Launches Dapagliflozin Tablets in the United States
leader Lupin Limited (Lupin) BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Farxiga® for the indications
More news about: Lupin Pharmaceutical, Inc.
Apr 10, 2026, 08:38 ET New Report Reinforces Efficacy of Oral Glutathione
key statistics: first, within a week of oral supplementation, GSH levels in whole blood elevated as high as 40%. In addition, administering 500mg and 1000mg doses had no noticeable difference among the participants."While the study was small and ongoing studies will be important, as far as preliminary
More news about: California Greens
Apr 10, 2026, 08:30 ET MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
placebo). Part 3A is designed to evaluate a one-step titration regimen with 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will evaluate a two-step titration regimen with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics
More news about: MetaVia Inc.
Apr 09, 2026, 17:14 ET Foundayo™ (orforglipron), la nueva pastilla GLP-1 de Lilly que se administra por vía oral para la pérdida de peso, ahora está disponible en Estados Unidos.
hospital más cercano.Más información Foundayo es una medicina recetada disponible en tabletas de 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, o 17.2 mg que se toman por vía oral. Llama al 1-800-545-5979 o visita
More news about: Eli Lilly and Company
Apr 09, 2026, 15:26 ET Powered Research at ARVO 2026
Neovascularization was induced via an IVT dose of DL-AAA in one eye of 4–6-month-old Dutch Belted rabbits. Control rabbits received a single 1 mg IVT dose of aflibercept 2.5 weeks post-induction. FA imaging via OCT was conducted 2-3 days prior to aflibercept administration and once weekly post-dose.
More news about: Powered Research, LLC
Apr 09, 2026, 13:11 ET DifGen Pharmaceuticals LLC, in Collaboration with Apotex Inc., Announces FDA Approval of Generic Nintedanib Soft Gel Capsules, 100 mg and 150mg Therapeutically Equivalent to Ofev®
approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Nintedanib Soft Gel Capsules, 100 mg and 150 mg. The approved product is therapeutically equivalent (AB-rated) to the reference listed drug, Ofev®. This approval represents a significant
More news about: DifGen Pharmaceuticals LLC
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
18.57%, to close at $5.50 per share on March 5, 2026. Then, on March 30, 2026, PepGen issued a press release announcing "clinical data from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1)." Although PepGen
More news about: Pomerantz LLP